AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02256332 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low dose plant based ingredient
Description: Reference food with low dose of plant based ingredient
Study NCT00263731 — intervention group
Intervention type: OTHER
Intervention: 13-C-glucose
Description: 10 grams of 13-C-glucose intravenously, as a 30-minute piggyback infusion, 2 to 6 hours prior to scheduled surgical resection of primary lung cancer.
Study NCT03146377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1250 mg/m2 BD orally for 1 week of a 2-week cycle (i.e. 1 week on, 1 week off)
Study NCT03146377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m2 IV on day 1 of a 2-week cycle
Study NCT03146377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 165 mg/m2 IV on day 1 of a 2-week cycle
Study NCT01199172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: voice hygiene
Description: subjects will receive voice hygiene training
Study NCT01199172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VH + VP
Description: subjects will be trained in voice hygiene and voice production training
Study NCT02549534 — intervention group
Intervention type: PROCEDURE
Intervention: Axon Reflexes
Description: \*Axon reflexes will be evoked in the palmar surface of the right great toe using local skin heating with a 0.33 cm2 heat probe using the following protocol:~* Baseline: Heating the skin of the toe for a minimum of 5 minutes at 33\*C.~* Heat Ramp: Increasing the heat in the heat probe to 42\*C at approx. 0.1\*C/10 sec.~* Skin Heating: Heating the skin of the toe for 30 minutes 42\*C.~* Heat Ramp: Increasing the heat in the heat probe to 44\*C at 0.1\*C/10 sec..~* Skin Heating: Heating the skin for an additional 5 minutes at 44\*C.~The size of the axon reflex during this skin heating protocol will be imaged using Laser Doppler Flowmetry (LDF). In the case that participants develop CIPN on their left side only, the left toe will be substituted.
Study NCT02549534 — intervention group
Intervention type: PROCEDURE
Intervention: Axon Flares
Description: Axon flares will be generated on the palmar surface of the right great toe using the same local skin heating protocol described above, and imaged using a laser speckle contrast imager (LSCI) (also known as full-field laser perfusion imager, or FLPI).
Study NCT03745118 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Byte Flies Sensor Dots
Description: Plastic pads that will be adhered to your chest area
Study NCT03745118 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Empatica E4
Description: wearable seizure detection wristband
Study NCT03745118 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Biovotion Everion
Description: wearable seizure detection device armband that is attached to upper arm
Study NCT03745118 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: GeneActiv
Description: wearable seizure detection watch
Study NCT02549534 — intervention group
Intervention type: PROCEDURE
Intervention: Self-Reported Signs & Symptoms of CIPN
Description: Self-reported signs \& symptoms of CIPN such as the presence and location of (1) tingling, (2) numbness, and (3) neuropathic pain, along with information about (4) deficits in vibration thresholds, and (5) loss of deep tendon reflexes will be assessed at each study visit using the 5-item, modified Total Neuropathy Score (mTNS).
Study NCT03376269 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HBOT
Description: •HBOT of 2 ATA for 90 minutes O2 100%, for 60 treatments
Study NCT03376269 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: creative art psychotherapy which includes self drawing and daily diary alongside professional psychotherapy sessions
Study NCT03376269 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychotherapy
Description: creative art psychotherapy which includes self drawing and daily diary alongside professional psychotherapy sessions
Study NCT03463512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Racecadotril plus ORS
Description: Racecadotril plus ORS
Study NCT03463512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ORS
Description: ORS
Study NCT01627483 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Medication review
Description: Assessment of risks of falls and fractures; medication review concerning fall-risk-increasing and fracture-preventing drugs; oral and written feed back of the results of the assessments and medication reviews to the hospital physician during the hospital stay and to the general practitioner 3 and 6 months after the hip fracture surgery.
Study NCT01627483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication review
Description: Assessment of risks of falls and fractures; medication review concerning fall-risk-increasing and fracture-preventing drugs; oral and written feed back of the results of the assessments and medication reviews to the hospital physician during the hospital stay and to the general practitioner 3 and 6 months after the hip fracture surgery.
Study NCT02931656 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aquatic exercise
Description: The aquatic exercise program will be under the professional guidance of a physiotherapist, with water at a temperature of around 26 to 28°C. The exercise sessions will be executed following the steps: 1) Heating (stretching and flexibility, static method, during 5'); 2) Aerobic exercise (running, displacements and combined movements of arms and legs, with 1minute interval, to 1minute activity and of during 20') 3) Spot exercises (strength / endurance of the upper and lower limbs and abdomen, using the resistance of water for 15') 4) Relaxation (slow walks for 5'). During the sessions of exercises the pregnant women will have heart rate monitored by the frequency meter (Polar Electro OY) to control the intensity of the exercises that will focus on the range of moderate intensity.
Study NCT02931656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic exercise
Description: The aquatic exercise program will be under the professional guidance of a physiotherapist, with water at a temperature of around 26 to 28°C. The exercise sessions will be executed following the steps: 1) Heating (stretching and flexibility, static method, during 5'); 2) Aerobic exercise (running, displacements and combined movements of arms and legs, with 1minute interval, to 1minute activity and of during 20') 3) Spot exercises (strength / endurance of the upper and lower limbs and abdomen, using the resistance of water for 15') 4) Relaxation (slow walks for 5'). During the sessions of exercises the pregnant women will have heart rate monitored by the frequency meter (Polar Electro OY) to control the intensity of the exercises that will focus on the range of moderate intensity.
Study NCT03872297 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: Consumption of a non active food complement during 3 months.~Tests performed :~* 2 blood tests :~* 2 body composition analysis via Dual-energy X-ray absorptiometry (DXA)~* 2 stool collections The first one of these analysis was performed at the beginning, second at the end of the study.
Study NCT03872297 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Naticol supplement
Description: Consumption of the active food complement during 3 months containing Naticol.~Tests performed :~* 2 blood tests :~* 2 body composition analysis via Dual-energy X-ray absorptiometry (DXA)~* 2 stool collections The first one of these analysis was performed at the beginning, second at the end of the study.
Study NCT04404062 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Membrane-based immunoassay kit
Description: The kit is a qualitative membrane-based immunoassay to detect IgG and IgM antibodies to SARS-CoV-2 in whole blood, serum or plasma specimens. IgG and IgM detection components are separate allowing for differential detection of each antibody.
Study NCT04404062 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative antibody Tests
Description: Antibody titres will be measured from whole blood samples taken from volunteers.
Study NCT04404062 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PCR Test
Description: PCR tests will be conducted on throat swabs taken from volunteers.
Study NCT04641858 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG-Denmark
Description: Participants randomized to receive BCG will receive one 0.1 ml dose of Mycobacterium bovis BCG live attenuated BCG-Denmark vaccine (AJ Vaccines, Copenhagen, Denmark) by intradermal injection in the left deltoid region.
Study NCT04641858 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Participants randomized to the control group will receive one 0.1 ml dose sterile 0.9 % NaCl by intradermal injection in the right deltoid region.
Study NCT04032548 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo mouthwash
Description: After using mouthwash for 21 days, they are instructed to refrain from mouthwash for 14 days (wash out period).
Study NCT04265378 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anodal tDCS
Description: Anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (current intensity of 1mA)
Study NCT04265378 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Intensive cognitive training
Description: Intensive cognitive training of a letter memory updating task and a 3-stage Markov decision making task, 9 sessions
Study NCT04265378 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive cognitive training
Description: Intensive cognitive training of a letter memory updating task and a 3-stage Markov decision making task, 9 sessions
Study NCT00149630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: Disulfiram 250 mg/day by mouth daily during study weeks 2-13. Disulfiram discontinued during study weeks 14-15.
Study NCT00149630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Initial dose 25 mg; increased by 5 mg at each subsequent daily dosing until 60 mg maintenace dose reached.
Study NCT00149630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Initial dose 25 mg; increased by 5 mg at each subsequent daily dosing until 60 mg maintenace dose reached.
Study NCT04032548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propolis mouthwash
Description: After using mouthwash for 21 days, they are instructed to refrain from mouthwash for 14 days (wash out period).
Study NCT00149630 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: 1-hour weekly, individual, manual-guided Cognitive Behaviorial Therapy.
Study NCT00149630 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: 1-hour weekly, individual, manual-guided Cognitive Behaviorial Therapy.
Study NCT00149630 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactose
Description: Lactose was added to both the active disulfiram and placebo doses so they tasted identical.
Study NCT00149630 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lactose
Description: Lactose was added to both the active disulfiram and placebo doses so they tasted identical.
Study NCT01174329 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Automatic neuro-electrostimulation by Saliwell Crown
Description: Continuous stimulation of the lingual nerve by Saliwell Crown
Study NCT01174329 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient-regulated neuro-electrostimulation by Saliwell Crown
Description: On-demand stimulation of the lingual nerveby Saliwell Crown
Study NCT01175707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Study NCT01175707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Study NCT02455687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hi-dose iv MgSO4
Study NCT02455687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hi-dose iv MgSO4
Study NCT02455687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized budesonide
Study NCT02455687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Std-dose iv MgSO4
Study NCT02455687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Std-dose iv MgSO4
Study NCT02455687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nebulized normal saline
Study NCT03223883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Oral supplement for 12 months
Study NCT03223883 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo for 12 months
Study NCT03357640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: combined oral contraceptive pills
Description: one package of oral contraception (Cilest containing norgestimate 250 microgram + ethinyl estradiol 35 microgram)
Study NCT03357640 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: combined oral contraceptive pills
Description: one package of oral contraception (Cilest containing norgestimate 250 microgram + ethinyl estradiol 35 microgram)
Study NCT04137874 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: eSTROKE model
Description: The eSTROKE model includes an electronic learning module, a full day course with practical teaching of National Institute of Health Stroke Scale and a mobile application which will be used for communication with in-hospital stroke physician
Study NCT04137874 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Conventional prehospital care
Study NCT02256332 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High dose plant based ingredient
Description: Reference food with high dose of plant based ingredient
Study NCT02256332 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Reference food format
Description: Reference food without plant-based ingredient
Study NCT01326052 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inferior Mesenteric Artery Preservation
Description: Performing left hemicolectomy the IMA was preserved ligating close to the colonic wall the sigmoids arteries.
Study NCT01326052 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inferior Mesenteric Artery Ligation
Description: Performing left hemicolectomy the IMA is ligated and sectioned after the origin of left colic artery
Study NCT03062904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Bronchodilators +/- Inhaled Methacholine
Description: 1. Combined Salbutamol 200μg and Ipratropium bromure 80μg (2 inhalations) if paradoxal answer~2. Inhaled Methacholine based on international recommendations
Study NCT04436627 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amadeo-assisted training-1
Description: Participants will receive 12-15 intervention sessions for about 3 consecutive weeks in a clinical setting (1 hour per session, 4-5 sessions per week). For each intervention session, participants will first receive 20 minutes active assistive training mode, followed by 20 minutes RT functional games (grasp and release) and 20 minutes RT finger coordination training.
Study NCT04436627 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amadeo-assisted training-2
Description: Participants will receive 12-15 intervention sessions for about 3 consecutive weeks in a clinical setting (1 hour per session, 4-5 sessions per week). For each intervention session, participants will first receive 10 minutes continuous passive motion mode followed by 20 minutes active assistive training mode, and 30 minutes RT functional games (grasp and release).
Study NCT04436627 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amadeo-assisted training-3
Description: Participants will receive 12-15 intervention sessions for about 3 consecutive weeks in a clinical setting (1 hour per session, 4-5 sessions per week). For each intervention session, participants will first receive 20 minutes continuous passive motion mode followed by 20 minutes active assistive training mode. After 40 minutes of RT, 20 minutes functional tasks without robot.
Study NCT01892033 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: 12 weeks of brisk walking
Study NCT03862079 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Given standard of care
Study NCT03862079 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Undergo FMT
Study NCT03862079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nystatin
Description: Given PO
Study NCT03862079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin-Tazobactam
Description: Given PO
Study NCT02351245 — intervention group
Intervention type: OTHER
Intervention: observation
Study NCT00736710 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: The rTMS procedures will be delivered in a single-blind fashion by the rTMS technician at the CAMH rTMS Laboratory. All subjects would be enrolled in a 10-week smoking cessation program using weekly group behavioral therapy which will emphasize psychoeducation about the effects of smoking on psychiatric and medical aspects of schizophrenia, social skills training, relapse-prevention skills training and benefits of quitting smoking. All subjects would start group therapy interventions in Week 1 of the trial, and begin rTMS procedures in a separate session on Week 2. The transdermal nicotine patch (TNP; 21 mg/24h) would be applied during the quit date at Week 3 (Day 15). At the end of the 10-week trial, TNP and group therapy would be discontinued.
Study NCT00736710 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: The rTMS procedures will be delivered in a single-blind fashion by the rTMS technician at the CAMH rTMS Laboratory. All subjects would be enrolled in a 10-week smoking cessation program using weekly group behavioral therapy which will emphasize psychoeducation about the effects of smoking on psychiatric and medical aspects of schizophrenia, social skills training, relapse-prevention skills training and benefits of quitting smoking. All subjects would start group therapy interventions in Week 1 of the trial, and begin rTMS procedures in a separate session on Week 2. The transdermal nicotine patch (TNP; 21 mg/24h) would be applied during the quit date at Week 3 (Day 15). At the end of the 10-week trial, TNP and group therapy would be discontinued.
Study NCT02965872 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT02752802 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic Coronary Angiogram
Description: Diagnostic angiographic procedure with the use of the DyeVert System.
Study NCT02622659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fuganlin Oral Liquid
Description: less than 1 years old: 5mL each time and three times a day~1\~3 years old: 10mL each time and three times a day~4\~6 years old: 10mL each time and four times a day~7\~12 years old: 10mL each time and five times a day
Study NCT04200963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IK-175
Description: Subjects will be administered IK-175 PO daily for every 21-day treatment cycle during the Single Agent Treatment dose escalation or for every 28-day treatment cycle during the Single Agent dose expansion.
Study NCT04200963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IK-175 and nivolumab
Description: Subjects will be administered IK-175 PO daily and administered a single dose of nivolumab IV on Day 1 for every 28-day treatment cycle during the Combination Treatment dose escalation and expansion.
Study NCT00789711 — intervention group
Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Evaluation of the safety profile and effectiveness of biphasic insulin aspart 30 in the treatment of diabetes mellitus under normal clinical practice conditions in the Philippines
Study NCT00789711 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: Evaluation of the safety profile and effectiveness of insulin detemir in the treatment of diabetes mellitus under normal clinical practice conditions in the Philippines
Study NCT02615288 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Study NCT04032548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: After using mouthwash for 21 days, they are instructed to refrain from mouthwash for 14 days (wash out period).
Study NCT02615288 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Study NCT03130049 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Popliteal plexus block
Description: 10 mL Marcain-adrenalin 5 mg/mL + 5 microgram/mL. Ultrasound-guided injection into the distal part of the adductor canal
Study NCT03606642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dual Antiplatelet (DAPT) Therapy
Description: DAPT - one of three (3) antiplatelet medications: ticagrelor (Brilinta), clopidogrel (Plavix) or prasugrel (Effient) with Aspirin.~Aspirin loading dose (LD) = 325 mg. Aspirin maintenance dose (MD) = 81 mg.~P2Y12 Inhibitor Loading Dose (investigator preference):~Clopidogrel 600 mg PO x 1 or 75 mg PO daily x 4; Prasugrel 60 mg PO x 1; Ticagrelor 180 mg PO x 1.~P2Y12 Inhibitor Maintenance Dose (investigator preference):~Clopidogrel 75 mg PO daily; Prasugrel 10 mg PO daily; Ticagrelor 90 mg PO BID.